I am a
Home I AM A Search Login

Papers of the Week

2020 Jun 19

Expert Opin Investig Drugs

Bile acid modulators for the treatment of nonalcoholic steatohepatitis (NASH).


Fiorucci S, Biagioli M, Sepe V, Zampella A, Distrutti E
Expert Opin Investig Drugs. 2020 Jun 19:1-10.
PMID: 32552182.


Nonalcoholic steatohepatitis (NASH) is a progressive form of nonalcoholic fatty liver disease (NAFLD) for which therapy is suboptimal. The farnesoid-X-receptor (FXR) and the G protein bile acid receptor (GPBAR)1 are two bile acid-activated receptors that exert regulatory effects on lipid, glucose, energy, and immune homeostasis. GPBAR1 and FXR ligands have shown efficacy in reversing steatohepatitis and fibrosis in preclinical models of NASH.